Pfizer Inc Joins £10 Million Bioprocessing Research Programme
News Mar 26, 2010
The BBSRC has announced the launch of the second round of funding for the Bioprocessing Industry Research Club (BRIC).
The 17 current industry members have agreed to continue their support for a second 5 year academic research programme, and are joined by new member, Pfizer Inc. Dr John Mott from the Pfizer, St Louis, USA laboratories spoke to a BRIC scientific meeting in Birmingham, where he described the importance of biopharmaceutical bioprocessing for Pfizer.
The club funds research in all aspects of bioprocessing of biologics, but applications in priority research areas will be particularly welcomed by the steering group that assesses applications:
• Bioprocessing research challenges for protein products and their host cell producers
• High-throughput bioprocess development
• Effective modeling of whole bioprocesses
• Robust and effective analytics for bioprocessing
• Bioprocessing research for cellular products.
New Method to Separate Mirrored Molecules Could Lead to Safer DrugsNews
The Dionne lab is developing an optical filter to sort chiral molecules, which could lead to purer and safer drugs and agrichemicals.READ MORE
APC Protein Deletion Disrupts Cell Signalling and Could Cause AutismNews
Researchers show deletion of the protein APC in progenitor cells leads to massive disruption of brain development and a signaling cascade previously linked to genes associated with autism.READ MORE
How do Poison Frogs Protect Themselves Against Their Own Neurotoxin?News
Scientists are a step closer to resolving a related head-scratcher, how do these frogs keep from poisoning themselves?READ MORE